secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-122778
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1
--------------------------------------------------------------------------------

- Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.
- CLN-978 (SLE) IND cleared in US and Australia; Phase 1 starts; initial data expected Q4 2025.
- Zipalertinib pivotal Phase 2b enrollment completed ahead of schedule; results mid-2025.
- CLN-619 expansion data in endometrial/cervical cancers expected Q2 2025; patent issued to 2041.
- R&D expense $35.5M, G&A $13.3M; both increased YoY from $33.8M and $11.0M respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024122778/0000950170-24-122778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024122778/cgem-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer